Curis Q1 2024 Earnings Report
Key Takeaways
Curis reported a net loss of $11.9 million, or $2.05 per share, for the first quarter of 2024. Revenues were $2.1 million, consisting of royalty revenues from Genentech/Roche's sales of Erivedge®. The company's cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024, and expects its existing resources will enable planned operations into 2025.
Topline update of clinical data from the TakeAim Leukemia study of emavusertib monotherapy in R/R AML patients to be released May 14, 2024.
Curis to present additional patient data in R/R AML patients with targeted mutations at ASCO and EHA conferences.
Updated clinical data from the TakeAim Leukemia study in mid-year 2024 and TakeAim Lymphoma study in late 2024.
Initial safety data from the frontline triplet combination study of emavusertib with azacitidine and venetoclax in patients with AML in late 2024.
Curis
Curis
Forward Guidance
Curis expects its existing cash, cash equivalents and investments will enable its planned operations into 2025.